WHO says it awaits full data from Merck on antiviral pill

Published by

GENEVA (Reuters) – The World Health Organization is awaiting full clinical data on the antiviral pill made by Merck & Co Inc to treat mild-to-moderate COVID-19 patients, a WHO spokesperson said on Tuesday, a day after the company said it had applied for U.S. emergency use authorisation. WHO spokesperson Christian Lindmeier, asked at a U.N. briefing in Geneva about the drug, said: “Indeed, this is an interesting development. We would have to see the full data about it. If it holds true, then it is another weapon in the fight against the COVID-19 pandemic.” The treatment, molnupiravir, cut the r…

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *